Compensated Awareness Post View
Disclaimer
BioLineRx Ltd. (BLRX) to Retain KCSA Strategic Communications
Located in Jerusalem, BioLineRx is a publicly-traded company focused on building a portfolio of products for unmet medical needs or with advantages over currently available therapies. Today, BioLineRx took a major step towards prominence with the announcement they have retained KCSA Strategic Communications to direct their U.S. investor relations program.
KCSA is a leading New York-based communications firm that intends to deploy a comprehensive investor relations program with the goal of expanding the influence BioLineRx has within the United States.
Todd Fromer, whom is a Managing Partner of KCSA will lead the KCSA team and provide strategic counsel on financial communication matters. In reference to KCSA being retained by BioLine Rx, Fromer stated, “Since listing its ADR’s on the NASDAQ in July, BioLineRx has had little exposure to the U.S. investment community. As such, we believe there is a tremendous opportunity for us to broaden awareness among investors and highlight the opportunity BioLineRx and its products provide. As part of our program, we will work with the BioLineRx management team to effectively and regularly communicate with its U.S. investor base.”
BioLine Rx CEO Dr. Kinneret Savitsky commented, “I am excited to begin working with KCSA in order to create greater awareness of BioLineRx in the U.S. investment community. We have several exciting products in our pipeline that are in advanced stage clinical trials, providing us with significant short-term and long-term opportunities to grow our business. With KCSA’s proactive communications program, we hope to highlight the ongoing development of these products to our shareholders and potential value of these products upon receiving regulatory market clearance.”
Currently, BioLineRx is trading in the $3.49 range. To learn more about the company as a whole, visit their website at: www.biolinerx.com
